Avalyn Pharma Inc. (NASDAQ:AVLN) Receives $59.00 Average PT from Analysts

Avalyn Pharma Inc. (NASDAQ:AVLN) has received an average rating of “Buy” from the five analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, two have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $59.00.

Several equities analysts have recently weighed in on the company. Evercore assumed coverage on Avalyn Pharma in a research report on Tuesday, May 26th. They set an “outperform” rating and a $51.00 target price on the stock. Wall Street Zen raised Avalyn Pharma to a “hold” rating in a research report on Saturday, May 9th. Guggenheim assumed coverage on Avalyn Pharma in a research report on Monday, May 25th. They set a “buy” rating and a $80.00 target price on the stock. Zacks Research raised Avalyn Pharma to a “hold” rating in a research report on Wednesday, May 27th. Finally, Morgan Stanley assumed coverage on Avalyn Pharma in a research report on Tuesday, May 26th. They set an “overweight” rating and a $53.00 target price on the stock.

Avalyn Pharma Stock Performance

NASDAQ:AVLN opened at $31.00 on Tuesday. Avalyn Pharma has a 1 year low of $24.15 and a 1 year high of $33.24. The business has a 50 day moving average price of $28.82.

Avalyn Pharma (NASDAQ:AVLN) last released its quarterly earnings data on Wednesday, June 3rd. The company reported ($21.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($16.38) by ($5.45).

Insider Activity at Avalyn Pharma

In related news, major shareholder Sr One Capital Management, Llc bought 555,555 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were purchased at an average price of $18.00 per share, with a total value of $9,999,990.00. Following the transaction, the insider owned 2,186,562 shares in the company, valued at $39,358,116. This trade represents a 34.06% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jill Carroll bought 277,778 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were bought at an average cost of $18.00 per share, for a total transaction of $5,000,004.00. Following the transaction, the director owned 2,186,562 shares in the company, valued at approximately $39,358,116. The trade was a 14.55% increase in their position. The SEC filing for this purchase provides additional information.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.